We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Nastech CEO Presents RNA Interference Pandemic Influenza Program at Beyond Genome Conference

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech Pharmaceutical Company Inc. has presented the company’s RNAi pandemic influenza program at Cambridge Healthtech Institute’s 5th annual RNA Interference conference.

Dr. Quay’s presentation summarized the results and status of Nastech’s siRNA pandemic influenza program and the company’s RNAi platform technology, delivery technology, and pre-clinical success with continued progression toward human clinical trials.